Eliquis vs Coumadin

Side-by-side comparison of Eliquis and Coumadin — mechanism, indications, safety, trials, sponsor, and pricing.

At a glance

EliquisCoumadin
Generic nameapixabanwarfarin
SponsorBristol-Myers SquibbGeneric (originally Wisconsin Alumni Research Foundation)
Drug classFactor Xa inhibitorVitamin K antagonist (anticoagulant)
Molecular targetFactor Xa (FXa)Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7
Modality—Small molecule
PhaseFDA-approvedFDA-approved
Therapeutic areaCardiovascularCardiovascular
First approval20121954-01-01

Mechanism of action

EliquisApixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development.
CoumadinInhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis.

Approved indications

Eliquis

  • Arterial embolus and thrombosis
  • Myocardial Reinfarction Prevention

Coumadin

  • Cerebral embolism
  • Deep Vein Thrombosis with Pulmonary Embolism
  • Deep venous thrombosis
  • Myocardial Reinfarction Prevention
  • Prevention of Thromboembolism with Chronic Atrial Fibrillation
  • Prevention of deep vein thrombosis
  • Pulmonary Thromboembolism Prevention
  • Pulmonary thromboembolism

Common side effects

Eliquis

  • Major Bleeding
  • Gastrointestinal Bleeding
  • Intracranial Hemorrhage
  • Hemorrhagic Stroke
  • Other Intracranial Hemorrhage

Coumadin

  • Hemorrhage
  • Nausea
  • Vomiting
  • Diarrhea
  • Rash
  • Abdominal pain
  • Pruritus
  • Dermatitis

Boxed warnings

Eliquis

No boxed warnings.

Coumadin

  • WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions ( 5.1 )] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration ( 2.1 )] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions ( 7 )] . Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see Patient Counseling Information ( 17 )] . WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. Warfarin sodium can cause major or fatal bleeding. ( 5.1 ) Perform regular monitoring of INR in all treated patients. ( 2.1 ) Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. ( 7 ) Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding. ( 17 )

Further reading